Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1809 results
September 2021
-
Story Access to Healthcare
Doing the right thing is good business
Lutz Hegemann shares how lessons learned treating patients with leprosy influenced the way he thinks about the pharmaceutical business.
-
Media Release
Novartis announces first FDA filing acceptance for anti-PD-1 antibody tislelizumab for people with esophageal cancer
Biologics License Application (BLA) submission supported by Phase III RATIONALE 302 trial, which met primary endpoint of improvement in overall survival (OS) in people with advanced or metastatic… -
Media Release
Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine
Sandoz enters into commercialization agreement for biosimilar bevacizumab with Bio-Thera Solutions, Ltd., for treatment of multiple types of cancers1,2Sandoz is committed to building on its leading… -
Story Patient Perspectives
A blood cancer patient’s long road to diagnosis
Ilona, a patient living with polycythemia vera, shares her experiences with this rare blood cancer
-
Pulse Update
Novartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients
-
Media Release
Novartis presents new findings at ERS reinforcing the efficacy of Enerzair® Breezhaler®, highlighting its digital companion, as well as showcasing commitment to low carbon footprint asthma solutions
Novartis will present 12 abstracts at the European Respiratory Society (ERS) International Congress 2021 for Enerzair® Breezhaler® (IND/GLY/MF*) and Atectura® Breezhaler® (IND/MF**) — for… -
Pulse Update
Novartis receives FDA fast track designation for LNA043 in osteoarthritis of the knee
-
Media Release
World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio® ▼(inclisiran)
Agreement follows positive NICE recommendation and commits to deliver Leqvio® (inclisiran) access via a population health management approach identifying eligible patients across England1 Over three…
August 2021
-
Media Release
Novartis Leqvio®* (inclisiran) analyses show effective and sustained LDL-C reduction in two sub-populations of patients with ASCVD
Separate post hoc analyses of pooled Phase III ORION-9, -10 and -11 data show twice-yearly** Leqvio® (inclisiran) consistently reduced low-density lipoprotein cholesterol (LDL-C) in patients with… -
Pulse Update
Novartis sabatolimab receives orphan drug designation from the European Commission for myelodysplastic syndromes
-
Media Release
Novartis presents important overall survival and quality-of-life results across solid tumor portfolio, among other key data at ESMO
New Kisqali® (ribociclib)* overall survival (OS) results from MONALEESA-2 trial in HR+/HER2− advanced breast cancer patients in the first-line settingHealth-related quality of life, pain and safety… -
Pulse Update
FDA accelerates review of Novartis STAMP inhibitor asciminib (ABL001) for patients with chronic myeloid leukemia (CML)